News | February 03, 2011

Behrman Capital Acquires Atherotech

February 3, 2011 – Behrman Capital, a private equity investment firm based in New York and San Francisco, has acquired Atherotech, a cardiometabolic testing services provider. Atherotech offers the VAP (Vertical Auto Profile) advanced lipid profile test.

The transaction closed on Dec. 23, 2010. The equity capital for the acquisition came from Behrman Capital IV L.P., with debt financing provided by MidCap Financial.

The VAP Test provides direct, detailed measurements of the lipid subclasses that cause cardiovascular disease. It was developed by Jere Segrest, M.D., director of the atherosclerosis research unit at the University of Alabama.

VAP technology more accurately identifies people at risk of heart disease than the traditional cholesterol tests developed in the 1970s, and does so at no significant additional cost. The profiles obtained by the test also allow physicians to create individualized treatment plans while continuing to track patients' progress in battling heart disease.

Robert Flaherty, an operating partner at Behrman Capital, will serve as chairman of the Board of Directors at Atherotech. Flaherty has more than 35 years of operating experience in the healthcare field, with particular expertise in the clinical laboratory environment. He previously served as president and CEO of Athena Diagnostics. During his 17-year tenure with the company, he grew Athena’s revenues from $3 million to $110 million and profits from zero to $50 million.

For more information:,

Related Content

Validation Studies Confirm High Accuracy of Novel HART AI-Driven Blood Tests
News | Blood Testing | March 19, 2019
Prevencio Inc. announced data confirming the high accuracy of its artificial intelligence (AI)-driven, multiple-protein...
CoaguChek XS PT Test Strips Recalled for Inaccurately Reporting High INR
News | Blood Testing | December 28, 2018
Terrific Care LLC. / Medex Supply Dist Inc. initiated a nationwide recall on Dec. 19 of Roche CoaguChek test strips, as...
Abbott Point-of-Care Blood Test Speeds Heart Attack Diagnosis
News | Blood Testing | October 26, 2018
For someone experiencing cardiac symptoms in the emergency room, every minute matters as physicians determine whether...
New Noninvasive Blood Glucose Test as Effective as Finger Prick

Image courtesy of University of Missouri School of Medicine

News | Blood Testing | October 24, 2018
For those living with diabetes, monitoring blood glucose accurately is necessary to prevent diabetes-related...
Abbott Receives CE Mark for High Sensitive Troponin-I Test
News | Blood Testing | October 16, 2018
October 16, 2018 — Abbott announced that its High Sensitive Troponin-I...
AI-Driven Blood Test Accurately Diagnoses Peripheral Artery Disease in Diabetic Patient
News | Blood Testing | September 04, 2018
Prevencio Inc. announced new data demonstrating its HART PAD test accurately diagnoses peripheral artery disease (PAD)...
More Sensitive Blood Test Diagnoses Heart Attacks Faster
News | Blood Testing | August 06, 2018
August 6, 2018 — A new test to assess a whether or not someone is having a...
Singulex cTnl Assay Can Identify Presence, Severity of CAD in Stable, Symptomatic Outpatients
News | Blood Testing | March 26, 2018
March 26, 2018 — Measurement of cardiac troponin in stable patients with chest pain using the ultra-sensitive Singule
Florida Medical Center First in State to Offer High Sensitive STAT Blood Test
News | Blood Testing | September 07, 2017
In July, The Heart Institute at Florida Medical Center became the first hospital in the state of Florida to offer the U...
Patients With Low Corus CAD Test Score Less Likely to Undergo Cardiac Referra
News | Blood Testing | May 02, 2017
CardioDx Inc. recently announced the publication of results from the multi-center, community-based PRESET Registry in...
Overlay Init